CMS Cochlear Implantation Coverage Policy Updated: What Billing Teams Need to Know (NCD 245)

CMS has issued a modification to National Coverage Determination 245, the federal policy governing Medicare coverage of cochlear implantation. The Centers for Medicare & Medicaid Services (CMS) updated NCD 245-v3 with an effective date of March 12, 2026, reinforcing the coverage framework established after the September 2022 review while clarifying the conditions under which beneficiaries may—or may not—qualify for this prosthetic device benefit. If your practice or health system performs cochlear implants on Medicare patients, understanding the precise eligibility criteria and non-coverage rules is essential to protecting your reimbursement.

What CMS NCD 245 Covers: Cochlear Implant Medicare Coverage Criteria

Cochlear implants are classified under the Medicare benefit category of Prosthetic Devices, which is an important framing for your billing team. The device itself is an electronic instrument with a surgically implanted component that stimulates auditory nerve fibers, paired with an external processor the patient wears or carries to capture, analyze, and code sound. Both single-channel and multi-channel models are addressed under this NCD.

Effective for services performed on or after September 26, 2022 (the baseline for the current coverage framework, carried forward in the 245-v3 update), CMS covers cochlear implantation for treatment of bilateral pre- or post-linguistic, sensorineural, moderate-to-profound hearing loss in individuals who demonstrate limited benefit from amplification.

The threshold for "limited benefit from amplification" is a specific, measurable standard: test scores of 60% or less correct in the best-aided listening condition on recorded tests of open-set sentence recognition. This is not a clinical judgment call—it's a documented, scored benchmark that must be in the patient's record before you submit a claim.

All Five Medicare Medical Necessity Criteria for Cochlear Implantation

CMS requires that patients meet every one of the following criteria for national coverage. A single unmet criterion moves the patient into the non-covered category:

1. Diagnosis of bilateral moderate-to-profound sensorineural hearing impairment with limited benefit from appropriate hearing aids or vibrotactile aids.
2. Cognitive ability to use auditory clues and a documented willingness to undergo an extended rehabilitation program.
3. Freedom from middle ear infection, an accessible cochlear lumen that is structurally suited to implantation, and freedom from lesions in the auditory nerve and acoustic areas of the central nervous system.
4. No contraindications to surgery.
5. FDA-approved labeling compliance—the device must be used strictly in accordance with Food and Drug Administration approval.

Each of these criteria should be explicitly documented in the clinical record before the claim is submitted. Vague or incomplete documentation is one of the most common reasons cochlear implant claims are denied or subjected to post-payment audit.

CMS Non-Coverage Rules: When Cochlear Implants Are Not a Medicare Benefit

Section C of NCD 245 is direct: Medicare beneficiaries who do not meet all five criteria listed above are not eligible for coverage—with one narrow exception.

If any single criterion is unmet, the implantation is considered nationally non-covered under standard Medicare. There is no appeals pathway based on clinical judgment alone when a patient falls outside these parameters under the standard coverage track.

Your patient intake and pre-authorization workflow should include a formal checklist against these five criteria before scheduling is finalized. A patient who is borderline on the open-set sentence recognition threshold (e.g., scoring 62%) does not qualify—and billing for that case without documentation of a passing score is exposure you don't want.

The Clinical Trial Exception: Coverage with Evidence Development

CMS does provide one pathway for patients who don't meet the standard coverage criteria: Coverage with Evidence Development (CED). Under Section D of NCD 245, CMS may cover cochlear implants for non-qualifying beneficiaries when the procedure is performed in the context of:

• FDA-approved Category B investigational device exemption (IDE) clinical trials, as defined at 42 CFR 405.201, or
• Routine costs in clinical trials under Section 310.1 of the National Coverage Determinations Manual.

If your cochlear implant program participates in qualifying research, this pathway is real and billable—but it requires that the trial itself be properly FDA-designated and that claims be submitted under the applicable clinical trial billing rules. CMS maintains a dedicated CED page for cochlear implantation that your compliance team should reference when evaluating trial eligibility.

Affected Codes

This policy does not list specific CPT or HCPCS codes in the NCD 245-v3 document. For applicable procedure and device codes, billing teams should reference:

• Transmittal 11875 (Medicare Claims Processing) — available at the CMS website
• Transmittal 11929 (Medicare Claims Processing) — available at the CMS website

These transmittals contain the claims processing instructions that govern how cochlear implantation is billed under this NCD. Your coding team should pull both documents and map them against your current charge description master entries.

If you use HCPCS codes for cochlear implant devices and components (as is common for DME and prosthetic billing), confirm those codes remain consistent with FDA-approved labeling per Criterion 5 above.

What Your Billing Team Should Do